Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. Welcome to the Q3 2025 Equestive Therapeutics, Inc. Earning Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star 1-1 on your telephone. You will then hear an automated message, advise your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Brian Cobb, please go ahead, sir. Thank you, operator. Good morning, and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer, and Ernie Toth, Chief Financial Officer. We're going to provide an overview of the company's recent business developments and performance for the third quarter of 2025, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Gary Slatko, Interim Chief Medical Officer, Sherry Korchinski, Chief Commercial Officer, Laurie Brander, Chief Legal Officer, and Peter Boyd, Chief People Officer. As a reminder, the company's remarks today correspond with the earnings release that was issued after market closed yesterday. In addition, a recording of today's call will be made available on Equesta's website within the Investors section shortly following the conclusion of this call. To remind you, the Equesta team will be discussing some non-GAAP financial measures this morning as part of its review of third quarter 2025 results. A description of these measures, along with a reconciliation to GAAP, can be found in the earnings release issued yesterday, which is posted on the investor section of Equestria's website. Duri...